Malhi Gin S, Mitchell Philip B, Salim Shahzad
School of Psychiatry, University of New South Wales, Randwick, Sydney, New South Wales, Australia.
CNS Drugs. 2003;17(1):9-25. doi: 10.2165/00023210-200317010-00002.
Bipolar depression is the predominant abnormal mood state in bipolar disorder. However, despite the key pertinence of this phase of the condition, the focus of research and indeed of clinical interest in the management of bipolar disorder has been mainly on mania. Bipolar depression has been largely neglected, and early studies often failed to distinguish depression due to major unipolar depression from that due to bipolar disorder. Consequently, many treatments used in the management of major depression have been adopted for use in bipolar depression without any robust evidence of efficacy. The selective serotonin reuptake inhibitors (SSRIs), bupropion, tricyclic antidepressants and monoamine oxidase inhibitors are all effective antidepressants in the management of bipolar depression. They are all associated with a small risk of antidepressant-induced mood instability. The mood stabilisers lithium, carbamazepine and valproate semisodium (divalproex sodium) all appear to have modest acute antidepressant properties. Among these, lithium is supported by the strongest data, but the use of lithium in the treatment of bipolar depression as a monotherapeutic agent is limited by its slow onset of action. Recently, there has been a growing body of evidence suggesting that lamotrigine may have particular effectiveness in both the acute and prophylactic management of bipolar depression. Clinical management of bipolar depression involves various combinations of antidepressants and mood stabilisers and is partly determined by the context in which the depressive episode occurs. In general, 'de novo' and 'breakthrough' (where the patient is already receiving medication) bipolar depression may be successfully managed by initiating mood stabiliser monotherapy, to which an antidepressant or second mood stabiliser may be added at a later date, if necessary. Breakthrough episodes of bipolar depression occurring in patients receiving combination therapy (two mood stabilisers or a mood stabiliser plus an antidepressant) require either switching of ongoing medications or further augmentation. If this fails, then novel strategies or ECT should be considered. Bipolar depression is a disabling illness and the predominant mood state for the vast majority of those with bipolar disorder. It therefore warrants prompt management once suitably diagnosed, especially as it is associated with a considerable risk of suicide and in the majority of instances is eminently treatable.
双相抑郁是双相情感障碍中主要的异常情绪状态。然而,尽管该疾病这一阶段具有关键相关性,但双相情感障碍管理方面的研究重点以及临床关注焦点主要集中在躁狂发作上。双相抑郁在很大程度上被忽视了,早期研究常常未能区分重度单相抑郁所致的抑郁与双相情感障碍所致的抑郁。因此,许多用于治疗重度抑郁的疗法被应用于双相抑郁,却没有任何有力的疗效证据。选择性5-羟色胺再摄取抑制剂(SSRIs)、安非他酮、三环类抗抑郁药和单胺氧化酶抑制剂在双相抑郁的治疗中都是有效的抗抑郁药。它们都有小概率引发抗抑郁药所致的情绪不稳定。心境稳定剂锂盐、卡马西平和丙戊酸半钠(丙戊酸钠)似乎都有一定程度的急性抗抑郁特性。其中,锂盐有最有力的数据支持,但锂盐作为单一治疗药物用于双相抑郁的治疗,因其起效缓慢而受到限制。最近,越来越多的证据表明,拉莫三嗪在双相抑郁的急性和预防性管理中可能具有特殊疗效。双相抑郁的临床管理涉及抗抑郁药和心境稳定剂的各种联合使用,部分取决于抑郁发作的背景情况。一般来说,“初发”和“突破性”(患者已在接受药物治疗)双相抑郁可以通过启动心境稳定剂单一疗法成功管理,如果有必要,之后可添加一种抗抑郁药或第二种心境稳定剂。接受联合治疗(两种心境稳定剂或一种心境稳定剂加一种抗抑郁药)的患者出现双相抑郁突破性发作时,需要更换正在使用的药物或进一步增加用药。如果这不起作用,那么应考虑采用新的策略或进行电休克治疗。双相抑郁是一种致残性疾病,是绝大多数双相情感障碍患者的主要情绪状态。因此,一旦确诊就应及时进行管理,特别是因为它与相当大的自杀风险相关,而且在大多数情况下是完全可治疗的。